Literature DB >> 15482785

Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.

Antonio La Marca1, Raoul Orvieto, Simone Giulini, Valerio Maria Jasonni, Annibale Volpe, Vincenzo De Leo.   

Abstract

The aim of the present study was to examine the relationship between Mullerian-inhibiting substance (MIS) levels and metabolic characteristics in women with polycystic ovary syndrome. Increased ovarian MIS production may exert a paracrine negative control on follicle growth sufficiently to prevent selection of a dominant follicle.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15482785     DOI： 10.1016/j.fertnstert.2004.06.001

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  25 in total

1.  Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients.

Authors:  Wenyan Xi; Fei Gong; Guangxiu Lu
Journal:  J Assist Reprod Genet       Date:  2012-03-02       Impact factor: 3.412

Review 2.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 3.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

4.  Endocrine disruptors, obesity, and cytokines - how relevant are they to PCOS?

Authors:  M Šimková; J Vítků; L Kolátorová; J Vrbíková; M Vosátková; J Včelák; M Dušková
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

5.  Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features.

Authors:  Melissa Pawelczak; Lisa Kenigsberg; Sarah Milla; Ying-Hua Liu; Bina Shah
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

Review 6.  Ontogeny of the ovary in polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Joanne S Richards
Journal:  Fertil Steril       Date:  2013-03-06       Impact factor: 7.329

7.  Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms.

Authors:  Sezai Sahmay; Yavuz Aydin; Mahmut Oncul; Levent M Senturk
Journal:  J Assist Reprod Genet       Date:  2013-12-18       Impact factor: 3.412

8.  Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index.

Authors:  Julie S Rios; Eleni A Greenwood; Mary Ellen G Pavone; Marcelle I Cedars; Richard S Legro; Michael P Diamond; Nanette Santoro; Fangbai Sun; Randal D Robinson; Gregory Christman; Heping Zhang; Heather G Huddleston
Journal:  J Clin Endocrinol Metab       Date:  2020-01-01       Impact factor: 5.958

9.  Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome.

Authors:  Heidi Cook-Andersen; Sandy S Chuan; Kevin Maas; Marcus A Rosencrantz; H Irene Su; Mark Lawson; Helen D Mason; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

10.  Increased Body Mass Index Is Associated With A Nondilutional Reduction in Antimüllerian Hormone.

Authors:  Eleni Greenwood Jaswa; Julie S Rios; Marcelle I Cedars; Nanette F Santoro; Mary Ellen G Pavone; Richard S Legro; Heather G Huddleston
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.